Palantir Down This Collapse: Is It Worth a Buy Now?
Palantir stock slides further from its 52-week high even after a standout Q4, as investors weigh a rich valuation aga...
Which No Fee Travel Card Is Better
Determine which no fee travel card is better suited for you. Make the right choice for your travel goals and preferences.
22,600 articlesTech Stocks Worth Buying: AI Dip with Triple-Digit Upside
As AI momentum pauses, three AI-driven tech stocks worth buying the dip emerge with signs of improving fundamentals a...
Multi-Billion-Dollar Cold Storage Giant Draws $19 Million Bet
A major cold storage leader caught the eye of a notable investor, who disclosed a fresh stake worth $19 million. This...
Fed's Favored Inflation Gauge Remains Elevated in January
January data shows the fed's favored inflation gauge staying elevated, underscoring persistent price pressures as pol...
Adobe Could Reach $420 by Year-End, JPMorgan Says
Adobe shares have a tough year, yet JPMorgan sees upside. A $420 year-end target hinges on improving ARR, rising RPO,...
Trump Memecoin Investors Offered Mar-a-Lago Meeting Soon
Top supporters of the TRUMP memecoin were invited to a Mar-a-Lago luncheon, creating on-chain buzz and calendar tensi...
Fastly's Sold Company Shares: Is the Stock a Buy Right Now
When a CEO disposes of stock, investors want context. This deep dive explains what fastly's sold company shares could...
Prediction: This Nuclear Stock Could Outperform the S&P This Year
A bold investing thesis centers on a single nuclear stock with big plans for small modular reactors and recycled fuel...
This Investor Sold Million: Why Biotech Shares Stay Bullish
A prominent investor dumped a multi‑million stake in a biotech stock that’s up double digits. This article explains w...
Micron Jumps Taiwan Factory on Acquisition, Earnings Catalyst
Micron Technology expands in Taiwan by acquiring Powerchip's P5 site, boosting DRAM and HBM capacity and setting up a...
These Stocks Cheaper Ways to Invest in Palantir’s Growth
As Palantir tightens its client base, investors are weighing shares of its partners as cheaper ways to ride Palantir'...
Stock Market Today, March: CytomX Surges on Positive Data
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status